Oxford Finance LLC

Oxford’s Leveraged Lending Team is pleased to announce the closing of a senior credit facility with Kashi Clinical Laboratories, in support of its partnership with Prairie Capital. The Company was founded in 2006 to provide high-resolution HLA typing for transplant donor matching. Over time, Kashi expanded its service offering to include post-transplant monitoring, genomic sequencing, and other diagnostic testing. Kashi enjoys industry-leading customer satisfaction and is renowned for its rapid turnaround time, scientific expertise, customer service and innovation using state-of-the-art technology.  

Oxford Finance is pleased to announce the appointment of David Hickman and Garrett Henn as Co-Heads of Oxford’s enterprise lending division, which includes life sciences, healthtech, and SaaS. David and Garrett collectively bring over four decades of lending expertise to their new leadership roles at Oxford, specializing in loan structuring and portfolio management for public and private life sciences, healthtech, and SaaS companies. View Full Press Release - https://shorturl.at/rPidJ

Oxford’s Leveraged Lending Team is pleased to announce the closing of a senior credit facility with Get Well, in support of its partnership with SAIGroup. Founded in 2000 and headquartered in Bethesda, MD, Get Well is a leading provider of patient engagement solutions which powers more than 10 million annual patient interactions at over 1,000 healthcare organizations. Get Well enhances the patient and clinician experience at the point of care and beyond, increasing clinician efficiency and delivering precision care recommendations for patients.

Oxford’s Leveraged Lending Team is pleased to announce the closing of a senior credit facility with Ellie Mental Health in support of its partnership with Princeton Equity Group. Founded in 2015 and headquartered in Mendota Heights, MN, Ellie is a leading provider of mental health services including individual, couples, and family counseling. Ellie has grown into a national provider with over 250 clinics throughout the United States.

Oxford’s Life Sciences Team is delighted to announce the closing of a debt financing agreement partnered with Innovatus Capital Partners of up to $180 million with Celcuity, a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. Proceeds from the transaction will assist in initiating a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistant. Link to Full Press Release - https://rb.gy/xzqvlt

Oxford’s Life Sciences Team is pleased to announce the expansion of our relationship with long-time client, Karius, a global leader in liquid biopsy for infectious diseases that harnesses metagenomics, next-generation sequencing, and artificial intelligence to enhance the precision and speed of pathogen diagnosis. The facility will support the continued commercial growth of the Karius Test® which can identify over 1,000 pathogens from a single blood draw and is used in over 300 healthcare institutions, including 90+ transplant centers and 40+ children’s hospitals across the United States.

Oxford’s Leveraged Lending Team is pleased to announce the closing of a senior credit facility with Lucent Health, in support of its partnership with Gauge Capital. Founded in 2014 and headquartered in Nashville, TN, Lucent is a leading third-party administrator and cost containment solution provider to self-insured employers across the United States. Lucent has established itself as a partner of choice through its ability to help employers reduce healthcare costs while simultaneously improving the member experience and health outcomes.

Oxford Finance is pleased to sponsor the upcoming eCap West Summit. We look forward to meeting you there to talk about financing for your transaction. Please reach out to Kevin Harbour or Richard Russakoff to connect with us.

Oxford’s Life Sciences Team is thrilled to announce the expansion of our relationship with long-time client, Pliant Therapeutics, a clinical-stage biopharmaceutical company leading the way in developing new treatments for fibrotic diseases. The facility will support the continued clinical development of PLN-74809, an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

View Full Press Release: https://shorturl.at/bvzO8